scholarly journals Short-Term Use of Dexamethasone/Netilmicin Fixed Combination in Controlling Ocular Inflammation After Uncomplicated Cataract Surgery

2021 ◽  
Vol Volume 15 ◽  
pp. 2847-2854
Author(s):  
Aldo Caporossi ◽  
Giovanni Alessio ◽  
Francesco Fasce ◽  
Giorgio Marchini ◽  
Antonio Rapisarda ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Fixed Combination ◽  
Ocular Inflammation ◽  
Short Term

scholarly journals Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution

2009 ◽  
pp. 199 ◽  
Author(s):  
Hyung Cho ◽  
Eric Wolf ◽  
Kenneth Wolf
Keyword(s):  
Cataract Surgery ◽  
Ophthalmic Solution ◽  
Ocular Inflammation

Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery

2009 ◽  
Vol 87 (3) ◽  
pp. 300-305 ◽  
Author(s):  
Masaru Miyanaga ◽  
Takashi Miyai ◽  
Ryohei Nejima ◽  
Yoko Maruyama ◽  
Kazunori Miyata ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Ophthalmic Solution ◽  
Ocular Inflammation

scholarly journals Tear lactoferrin concentration during postoperative ocular inflammation in cataract surgery

2009 ◽  
Vol 75 (2) ◽  
pp. 142-144 ◽  
Author(s):  
Raj Kumar ◽  
I. P. S. Parmar ◽  
Neelam Chhillar ◽  
Harbans Lal
Keyword(s):  
Cataract Surgery ◽  
Ocular Inflammation

New Look at Ocular Inflammation Control – Powerful and Fast-acting Twice-daily Bromfenac for a Novel Standard in the Treatment of Inflammation

2011 ◽  
Vol 05 (01) ◽  
pp. 20 ◽  
Author(s):  
Hyung Cho ◽  
Arash Mozayan ◽  
◽  
Keyword(s):  
Intraocular Pressure ◽  
Adverse Events ◽  
Cataract Surgery ◽  
Synergistic Effects ◽  
Safety Data ◽  
Ocular Inflammation ◽  
Prostaglandin E ◽  
Ophthalmic Surgery ◽  
Inflammatory Conditions ◽  
Increased Risk

Inflammation in the eye arising from various factors – including allergy, infection, injury and surgery – can have serious consequences, and can continue long after the cause is removed, resulting in permanently damaged vision. The treatment of ophthalmic inflammation after surgery has traditionally consisted of topical corticosteroids, but adverse events such as delayed healing, rise in intraocular pressure and increased susceptibility to microbial infections have driven the search for alternative treatments. Non-steroidal anti-inflammatory drugs (NSAIDs) have been used as alternatives to steroid treatments but also have limitations and cause adverse events. Bromfenac has emerged as a potent and safe treatment for inflammation after cataract surgery. Its unique chemical structure makes it a highly lipophilic molecule that penetrates all major ocular tissues in a rapid and sustained manner. It is also a potent inhibitor of the enzyme cyclo-oxygenase-2, which is believed to be the primary mediator of ocular inflammation. These properties permit less frequent dosing (twice-daily [BID]) and greater patient tolerability. A body of efficacy and safety data support use of bromfenac in this indication and it compares favourably with other NSAIDs and steroids in limiting post-operative inflammation. NSAIDs and corticosteroids have different, potentially synergistic effects. However, benefits specific to NSAIDs include lowering prostaglandin E-induced intraocular pressure elevation, no increased risk of secondary infections and stabilisation of the blood–aqueous barrier. With increasing demand for ophthalmic surgery, bromfenac and other treatments are likely to be important components in the treatment of inflammatory conditions after cataract surgery, decreasing pain and contributing to favourable visual outcomes.

Treatment of Post-operative Inflammation following Cataract Surgery – A Review

2012 ◽  
Vol 06 (02) ◽  
pp. 98 ◽  
Author(s):  
Harminder S Dua ◽  
Richa Attre ◽  
◽  
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Cataract Surgery ◽  
Healthcare Providers ◽  
Surgical Techniques ◽  
Ocular Inflammation ◽  
Effective Control ◽  
Loteprednol Etabonate ◽  
Design Modification

Inflammation after cataract surgery, which can be persistent, remains an undesirable consequence despite many advances in surgical techniques. Although corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have traditionally been used to treat inflammation, prophylactically as well as post-operatively, there are no established guidelines for the treatment of inflammation induced by cataract surgery. The long-term use of corticosteroids has raised safety concerns, especially with regard to elevated intraocular pressure (IOP). This limitation of traditional corticosteroids led to the development of C-20 ester corticosteroids through retrometabolic drug design. This design modification allows the corticosteroid to be active at its site of action and then undergo predictable hydrolysis to inactive metabolites, resulting in reduced side effects. A review of studies published in the last 10 years indicates that C-20 ester corticosteroids provide effective control of post-cataract surgery inflammation without the elevation of IOP. Loteprednol etabonate ophthalmic suspension 0.5 % is the only topical C-20 ester corticosteroid approved for use in the treatment of corticosteroid-responsive inflammatory conditions including post-operative ocular inflammation. This corticosteroid, alone or in combination with NSAIDs, may provide effective and safe inflammation control, especially for high-risk patients, and may overcome concerns regarding side effects associated with traditional C-20 ketone corticosteroids. Ocular inflammation after cataract surgery presents healthcare providers with a treatment dilemma. While corticosteroids are traditionally the therapy of choice for inflammation, their long-term use for managing ocular inflammation can produce significant adverse events. This article discusses whether C-20 ester corticosteroids, alone or in combination with NSAIDs, offer effective treatment of post-cataract surgery inflammation while minimising adverse events.

Sign in / Sign up

Export Citation Format

Share Document